Compare Vanguard Total World Stock Index Fund ETF (VT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total World Stock Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Total World Stock Index Fund ETF trades at $159.53 (market cap $101.70B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 10.1× State Street SPDR S&P Biotech ETF's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Total World Stock Index Fund ETF for 53 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| VT | XBI | |
|---|---|---|
Market Cap | $101.70B | $10.11B |
Volume | 1,783,794 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $162.39 | $169.55 |
52-Week Low | $134.19 | $104.99 |
Typical Hold Time | 53 Days | 37 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VT trades at $159.64, down 0.66% on the day, with technical indicators showing a bullish bias in moving averages while oscillators remain neutral. The ETF maintains strong global diversification with over 9,700 stocks across developed and emerging markets. Recent news highlights VT's competitive positioning against international-focused ETFs, with Seeking Alpha maintaining a Buy rating and targeting 6-10% returns over the next 6-12 months.
VT offers comprehensive global equity exposure with a low 0.06% expense ratio, though key financial ratios remain unavailable. The outlook remains positive for long-term diversification, with risks including currency fluctuations and geopolitical tensions. Institutional activity shows mixed signals with both position increases and decreases reported in recent quarters.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
